Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $64000.0.

  • Fulcrum Therapeutics' Cash from Financing Activities fell 8992.13% to $64000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $448000.0, marking a year-over-year decrease of 8481.36%. This contributed to the annual value of $2.7 million for FY2024, which is 9767.53% down from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Cash from Financing Activities is $64000.0, which was down 8992.13% from $301000.0 recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Cash from Financing Activities high stood at $137.9 million for Q3 2021, and its period low was $64000.0 during Q3 2025.
  • Its 5-year average for Cash from Financing Activities is $23.1 million, with a median of $377000.0 in 2024.
  • Within the past 5 years, the most significant YoY rise in Fulcrum Therapeutics' Cash from Financing Activities was 16624819.28% (2021), while the steepest drop was 9967.69% (2021).
  • Fulcrum Therapeutics' Cash from Financing Activities (Quarter) stood at $891000.0 in 2021, then tumbled by 75.53% to $218000.0 in 2022, then surged by 31.65% to $287000.0 in 2023, then crashed by 71.08% to $83000.0 in 2024, then decreased by 22.89% to $64000.0 in 2025.
  • Its last three reported values are $64000.0 in Q3 2025, $301000.0 for Q2 2025, and $83000.0 during Q4 2024.